Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024
30 Avril 2024 - 2:00PM
Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will
report its first quarter financial results after the close of the
U.S. markets on Tuesday May 7, 2024. Following the release, the
company will host a live conference call and webcast at 4:30 p.m.
ET.
To participate in the conference call, dial 1-800-715-9871 and
provide the passcode 6363041. International callers may dial
1-646-307-1963 and use the same passcode. In addition, a live audio
of the conference call will be available as a webcast. Interested
parties can access the event through the “Events” page on the
Pacira website at investor.pacira.com.
About Pacira
Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to
providing a non-opioid option to as many patients as possible to
redefine the role of opioids as rescue therapy only. The company is
also developing innovative interventions to address debilitating
conditions involving the sympathetic nervous system, such as
cardiac electrical storm, chronic pain, and spasticity. Pacira has
three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine
liposome injectable suspension), a long-acting, local analgesia
currently approved for postsurgical pain management; ZILRETTA®
(triamcinolone acetonide extended-release injectable suspension),
an extended-release, intra-articular, injection indicated for the
management of osteoarthritis knee pain; and ioveraº®, a novel,
handheld device for delivering immediate, long-acting, drug-free
pain control using precise, controlled doses of cold temperature to
a targeted nerve. To learn more about Pacira, including the
corporate mission to reduce overreliance on opioids, visit
www.pacira.com.
Investor Contact:
Pacira BioSciences, Inc.
Christian Pedetti, (973) 254-4387
Christian.Pedetti@pacira.com
Pacira BioSciences (NASDAQ:PCRX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Pacira BioSciences (NASDAQ:PCRX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024